Real-World Utilization of an Intrauterine, Vacuum-Induced, Hemorrhage-Control Device

Authors:
  • KRKara M. Rood
    Kara M. Rood
  • ABAngela Bianco
    Angela Bianco
  • JBJoseph R. Biggio
    Joseph R. Biggio
  • PDPaul Dietz
    Paul Dietz
  • KDKelly Msn Drake
    Kelly Msn Drake
  • EHErica Heilman
    Erica Heilman
  • MHMaeve Hopkins
    Maeve Hopkins
  • MJMonique De Four Jones
    Monique De Four Jones
  • TKTyler Katz
    Tyler Katz
  • CMCourtney Do Martin
    Courtney Do Martin
  • MPMona Prasad
    Mona Prasad
Open Access
Publisher website
Google Scholar
Abstract
OBJECTIVE: To assess the real-world effectiveness and safety of a U.S. Food and Drug Administration (FDA)–cleared intrauterine vacuum-induced-hemorrhage control device for postpartum hemorrhage (PPH) management. METHODS: Sixteen centers in the United States participated in this observational, postmarket registry medical record review (October 2020 through March 2022). The primary effectiveness outcome was treatment success, defined as bleeding control after insertion with no treatment escalation or bleeding recurrence. Additional outcomes included blood loss, time to device insertion, indwelling time, bleeding recurrence, and time to bleeding control. Treatment success and severe maternal morbidity measures (transfusion of 4 or more units of red blood cell, intensive care unit admission, and hysterectomy) were evaluated by blood loss before insertion. To assess safety, serious adverse events (SAEs) and adverse device effects were collected. All outcomes were summarized by mode of delivery; treatment success was summarized by bleeding cause (all causes, any atony, isolated atony, nonatony). RESULTS: In total, 800 individuals (530 vaginal births, 270 cesarean births) were treated with the device; 94.3% had uterine atony (alone or in combination with other causes). Median total blood loss at device insertion was 1,050 mL in vaginal births and 1,600 mL in cesarean births. Across all bleeding causes, the treatment success rate was 92.5% for vaginal births and was 83.7% for cesarean births (95.8% [n=307] and 88.2% [n=220], respectively, in isolated atony). Median indwelling time was 3.1 hours and 4.6 hours, respectively. In vaginal births, 14 SAEs were reported among 13 individuals (2.5%). In cesarean births, 22 SAEs were reported among 21 individuals (7.8%). Three (0.4%) SAEs were deemed possibly related to the device or procedure. No uterine perforations or deaths were reported. CONCLUSION: For both vaginal and cesarean births in real-world settings, rapid and effective bleeding control was achieved with an FDA-cleared intrauterine vacuum-induced hemorrhage-control device. The safety profile was consistent with that observed in the registrational trial (NCT02883673), and SAEs or adverse device effects were of the nature and severity expected in the setting of PPH. This device is an important new tool for managing a life-threatening condition, and timely utilization may help to improve obstetric hemorrhage outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04995887.
Funding Information
  • Alydia Health Inc and Organon & Co

This publication has 15 references indexed in Scilit: